Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Osteosarcoma Maintenance Therapy With OST31-164

Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled. Patients will receive OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.

  • 5 views
  • 16 Jan, 2022
  • 3 locations
Olaparib With Ceralasertib in Recurrent Osteosarcoma

This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: Olaparib Ceralasertib

olaparib
measurable disease
neutrophil count
kidney function tests
cancer
  • 0 views
  • 21 Oct, 2021
  • 2 locations
Gemcitabine Docetaxel and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

This phase I/II trial studies the side effects and best dose of hydroxychloroquine and how well it works when given together with gemcitabine and docetaxel in treating participants with osteosarcoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as gemcitabine, docetaxel, and hydroxychloroquine, …

refractory osteosarcoma
neutrophil count
measurable disease
methotrexate
tumor cells
  • 1 views
  • 23 Jan, 2021
  • 1 location
Cabozantinib With Topotecan-Cyclophosphamide

This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. The names of the drugs are: Cabozantinib Topotecan Cyclophosphamide The names of the non-investigational supportive care drugs are: Filgrastim, pegfilgrastim, or a related growth factor.

  • 0 views
  • 07 Oct, 2021
  • 2 locations
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.

biologic agent
lipase
measurable disease
myelosuppressive chemotherapy
systemic therapy
  • 0 views
  • 17 Jan, 2022
  • 5 locations
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

(relapsed) or does not respond to treatment (refractory) or relapsed osteosarcoma. Magrolimab and dinutuximab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread

  • 0 views
  • 21 Jan, 2022
  • 5 locations
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Because there is no standard treatment at this time, patients are …

cytokines
refractory neuroblastoma
tumor cells
liver disease
cancer
  • 10 views
  • 26 Nov, 2021
  • 2 locations
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

This phase I trial investigates the side effects and determines the best dose of an immune cell therapy called GD2CART, as well as how well it works in treating patients with osteosarcoma or neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory). T cells are infection …

  • 0 views
  • 07 Jan, 2022
  • 1 location
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent Resectable Osteosarcoma

The purpose of this study is to evaluate the safety and efficacy of nivolumab, or nivolumab in combination with azacitidine in participants with recurrent, resectable osteosarcoma

metastatic disease
cancer chemotherapy
azacitidine
metastasis
resectable osteosarcoma
  • 35 views
  • 17 Sep, 2021
  • 24 locations
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)

This is a Phase I clinical trial evaluating abemaciclib (LY2835219), an inhibitor of cyclin dependent-kinases 4 and 6 (Cdk 4/6) in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum A) and in relapsed/refractory/progressive malignant brain (Grade III/IV, including DIPG; MBT) and solid tumor (ST) patients …

biologic agent
myelosuppressive chemotherapy
dexamethasone
corticosteroids
metastasis
  • 127 views
  • 29 Jan, 2022
  • 5 locations